187 related articles for article (PubMed ID: 2705754)
1. Cytotoxicity of N4-behenoyl-1-beta-D-arabinofuranosylcytosine through gradual conversion to 1-beta-D-arabinofuranosylcytosine in HeLa cells.
Maehara Y; Kusumoto T; Sakaguchi Y; Kusumoto H; Anai H; Sugimachi K
Anticancer Res; 1989; 9(1):41-4. PubMed ID: 2705754
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine after intraperitoneal administration].
Noda T; Oku M; Kiyozuka Y; Maruyama M; Adachi S; Akada S; Okamura Y; Ichijo M
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2929-35. PubMed ID: 3178241
[TBL] [Abstract][Full Text] [Related]
4. Effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on blast progenitors of acute myeloblastic leukemia.
Nara N; Tohda S; Suzuki T; Nagata K; Yamashita Y; Imai Y; Maruyama Y; Tomiyama J
Cancer Res; 1990 Dec; 50(23):7587-92. PubMed ID: 2253209
[TBL] [Abstract][Full Text] [Related]
5. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
Oh-ishi J; Kataoka T; Tsukagoshi S; Sakurai Y; Shibukawa M; Kobayashi H
Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444
[TBL] [Abstract][Full Text] [Related]
6. In vitro sensitivity of various human tumors to 1-beta-D-arabinofuranosylcytosine and N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
Maehara Y; Kusumoto T; Kusumoto H; Anai H; Sugimachi K
Chemotherapy; 1989; 35(3):181-6. PubMed ID: 2766858
[TBL] [Abstract][Full Text] [Related]
7. Membrane affinity and metabolism of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine into cultured KB cells.
Tsuruo T; Iida H; Hori K; Tsukagoshi S; Sakurai Y
Cancer Res; 1981 Nov; 41(11 Pt 1):4484-8. PubMed ID: 7306971
[TBL] [Abstract][Full Text] [Related]
8. [The simultaneous determination of Ara-U and Ara-C, urinary metabolites of N4-behenoyl-1-beta-D-arabinofuranosylcytosine by mass fragmentography (author's transl)].
Makino Y; Matsubara Y; Watanabe K; Hirobe M
Yakugaku Zasshi; 1982 Jan; 102(1):49-55. PubMed ID: 7086638
[No Abstract] [Full Text] [Related]
9. [Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
Yoshida T; Nakamura S; Ohtake S; Ito K; Kobayashi K; Kanno M; Hirai J; Tachimori K; Matsuda T
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1820-4. PubMed ID: 3592717
[TBL] [Abstract][Full Text] [Related]
10. Antiviral effect of antileukemic drugs N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus.
Nakamura K; Eizuru Y; Kumura K; Minamishima Y
J Med Virol; 1990 Jun; 31(2):141-7. PubMed ID: 1696958
[TBL] [Abstract][Full Text] [Related]
11. Intracellular distribution of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in blood cells.
Ueda T; Nakamura T; Kagawa D; Yamamoto K; Uchida M; Sasada M; Uchino H
Gan; 1983 Jun; 74(3):445-51. PubMed ID: 6884702
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
Yamada K; Kawashima K; Kato Y; Morishima Y; Tanimoto M; Ohno R
Recent Results Cancer Res; 1980; 70():219-29. PubMed ID: 6766563
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
[TBL] [Abstract][Full Text] [Related]
15. [Experimental study on the correlation between the antitumor activity and pharmacokinetics of cytosine arabinoside (Ara-C) and N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC)].
Takenaka T; Kimura K
Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2322-8. PubMed ID: 3831176
[No Abstract] [Full Text] [Related]
16. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
Koller-Lucae SK; Suter MJ; Rentsch KM; Schott H; Schwendener RA
Drug Metab Dispos; 1999 Mar; 27(3):342-50. PubMed ID: 10064564
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-beta-D-arabinofuranosylcytosine by cyclopentenyl cytosine.
Grem JL; Allegra CJ
Cancer Res; 1990 Nov; 50(22):7279-84. PubMed ID: 1699659
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
Watanabe A; Kuriyama H; Kiyota T
Gan To Kagaku Ryoho; 1996 Feb; 23(3):291-6. PubMed ID: 8712821
[TBL] [Abstract][Full Text] [Related]
19. A radioimmunoassay method for 1-beta-D-arabinofuranosyluracil using antibodies directed against 1-beta-D-arabinofuranosylcytosine.
Okabayashi T; Mihara S; Moffatt JG
Cancer Res; 1977 Feb; 37(2):625-8. PubMed ID: 12864
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
Grant S; Bhalla K; Rauscher F; Cadman E
Cancer Res; 1983 Nov; 43(11):5093-100. PubMed ID: 6577943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
